Physician profile
Mandy Wever
NPI 1316220296
$526.37
in general payments reported to CMS, 2019-2025
15 companies · $57.90 in 2025
The $57.90 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.66 · 2022: $136 · 2023: $82.76 · 2024: $169 · 2025: $57.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.23 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.89 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $88.74 | 2023-2024 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $62.66 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $36.08 | 2023-2024 | |
| Genzyme Corporation | $35.56 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $32.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.67 | 2022 | |
| Janssen Biotech, INC. | $15.01 | 2024 | Tremfya |
| Amgen INC. | $14.53 | 2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $14.06 | 2023 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2023 | Sotyktu |
| Biofrontera INC. | $13.14 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $12.54 | 2021 | |
| Leo Pharma INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Wever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.